471 related articles for article (PubMed ID: 31463793)
1. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
2. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
Ashtekar SS; Bhatia NM; Bhatia MS
Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
[TBL] [Abstract][Full Text] [Related]
3. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
4. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
5.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
6. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
Kulkoyluoglu E; Madak-Erdogan Z
Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
[TBL] [Abstract][Full Text] [Related]
7. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
8. Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.
Bafna D; Ban F; Rennie PS; Singh K; Cherkasov A
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545494
[TBL] [Abstract][Full Text] [Related]
9. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
10. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
11. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach.
Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J
Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862
[TBL] [Abstract][Full Text] [Related]
12. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal estrogen receptor isoform-selective biphenyls.
Bhatnagar S; Soni A; Kaushik S; Rikhi M; Santhoshkumar TR; Jayaram B
Chem Biol Drug Des; 2018 Feb; 91(2):620-630. PubMed ID: 29052968
[TBL] [Abstract][Full Text] [Related]
14.
Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
[TBL] [Abstract][Full Text] [Related]
15. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
16. Induced Fit Docking and Automated QSAR Studies Reveal the ER-α Inhibitory Activity of Cannabis sativa in Breast Cancer.
Kikiowo B; Ogunleye AJ; Iwaloye O; Ijatuyi TT; Adelakun NS; Alashe WO
Recent Pat Anticancer Drug Discov; 2021; 16(2):273-284. PubMed ID: 33563181
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Selective ERα/ERβ Ligands by Multi-pharmacophore Modeling and Virtual Screening.
Huang W; Wei W; Yang Y; Zhang T; Shen Z
Chem Pharm Bull (Tokyo); 2015; 63(10):780-91. PubMed ID: 26423034
[TBL] [Abstract][Full Text] [Related]
19. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
Clusan L; Le Goff P; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
[TBL] [Abstract][Full Text] [Related]
20. Anabolic effect of the traditional Chinese medicine compound tanshinone IIA on myotube hypertrophy is mediated by estrogen receptor.
Zhao P; Soukup ST; Hegevoss J; Ngueu S; Kulling SE; Diel P
Planta Med; 2015 May; 81(7):578-85. PubMed ID: 26018796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
